appointing. As point mutations in codon 12 of the c-Ki-ras 2 gene are found in most pancreatic adenocarcinoma and not in chronic pancreatitis, this study analysed prospectively the presence of these mutations in brushing samples collected during ERCP in 45 patients (26 (Invitrogen) were transformed with the pCR II vector containing polymerase chain reaction products using the same kit and plated on Luria-Bertani medium-Agar plates with ampicillin 50 pug/ml and X-Gal 40 mg/ml for selection.
Selected colonies were grown in LuriaBertani medium+ampicillin medium for DNA plasmid isolation using a Quiagen plasmid mini Kit (Quiagen Inc, Chatsworth, CA, USA). Polymerase chain reaction products were directly sequenced by the dideoxy chain termination sequencing method2' using Sequenase version 2.0 DNA sequencing Kit (United States Biochemical, Cleveland, Ohio) according to the manufacturer's instructions. In all 20 patients showing a clearly visualised 99 bp band (type (a) and (c) results), mutations at codon 12 were confirmed by direct sequencing (Fig 2, sequences 1 and 3) ; the more frequent mutation detected was GTT in place of GGT.
By contrast, in the eight patients with type (b) results, we failed to detect any mutation (Fig 2, sequence 2) . In addition, direct sequencing was performed in five patients with type (d) results where normal Ki-ras codon 12 (Table III) . Two of them were suspected to have malignant degeneration and therefore had surgical resection. Histological tests showed intraductal mucin hypersecreting neoplasm with mild to moderate dysplasia. Three other older patients, with good clinical status did not experience complications such as secondary obstructive pancreatitis and are followed up by imaging techniques, including ERCP, endoscopic ultrasonography, and computed tomography, and brush cytology (mean (SD) follow up 11.4 (1.6) months, range 9-13). In the five cases, the tumour was thus considered as benign. 15 In this study, we found the mutation in six patients with small size tumours (S2 cm). It is critical to assess in the future the effectiveness of this approach in early neoplasia detection. A longterm study of Ki-ras mutations incidence in chronic pancreatitis patients and their relation to clinical, radiological, and cytological changes would be of interest.
A similar approach might be applicable to intraductal mucin hypersecreting neoplasm, although Ki-ras mutation incidence in this disease is controversial and based on a limited number of patients. Differences exist between Japanese and occidental reports. The first23 24 found Ki-ras mutations in respectively three of five and five of eight patients with intraductal papillary neoplasms while the second'3 did not see any mutation in a series of five patients. Our results did not show the presence of the mutated Ki-ras gene in the five patients with intraductal mucin hypersecreting neoplasm, which is similar to intraductal papillary neoplasm.18 25 In this small series, Ki-ras analysis did not permit discrimination of chronic pancreatitis from intraductal mucin hypersecreting neoplasm while cytological findings were more suggestive. It should be emphasised, however, that none of our intraductal mucin hypersecreting neoplasms had histological or cytological features of severe dysplasia or atypia and were thus considered to have a favourable prognosis. As this type of neoplasm has a low malignant potential but is often responsible for the development of secondary obstructive pancreatitis,'8 25 
